Back to top
more

Abbott Laboratories (ABT)

(Delayed Data from NYSE)

$127.29 USD

127.29
5,452,778

+1.10 (0.87%)

Updated Aug 1, 2025 03:59 PM ET

After-Market: $127.29 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 30% (173 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

QuidelOrtho Stock Down Despite Solid Preliminary Q4 Revenues

by Zacks Equity Research

QDEL's preliminary fourth-quarter revenues align with the company's expectations.

Zacks Equity Research

Macroeconomic Woes, Competition Weigh on TMO's Stock Performance

by Zacks Equity Research

The industry-wide trend of difficult macroeconomic conditions is creating a challenging business environment for Thermo Fisher.

Zacks Equity Research

DexCom Stock Up Following Strong Preliminary Q4 Results & 2025 Outlook

by Zacks Equity Research

DXCM's top line reflects strong demand for its CGM sensors. International expansion is also driving sales higher. Gross margin reflects inventory damage.

Zacks Equity Research

TEM Stock Declines Following Preliminary Q4 Sales Miss

by Zacks Equity Research

Tempus reports strong 2024 growth and unveils a bold 2025 outlook with 75% revenue growth and innovative diagnostics.

Zacks Equity Research

BRKR Stock Up on the Launch of LUMOS II ILIM QCL-Based IR Microscope

by Zacks Equity Research

Bruker launches LUMOS II ILIM QCL-based IR microscope for pharma and life science research.

Zacks Equity Research

Abbott (ABT) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

The latest trading day saw Abbott (ABT) settling at $113.19, representing a +0.78% change from its previous close.

Zacks Equity Research

PacBio Stock May Gain Following the Collaborated Launch of GutID

by Zacks Equity Research

PACB and Intus Bio collaborate to launch GutID, the first commercial human gut health test.

Zacks Equity Research

Here's Why You Should Retain DexCom Stock in Your Portfolio for Now

by Zacks Equity Research

DXCM continues to raise optimism among investors owing to its strong product portfolio.

Zacks Equity Research

WBA Q1 Earnings and Revenues Beat Estimates, Stock Up in Pre-Market

by Zacks Equity Research

Walgreens delivers better-than-expected earnings and revenues in the first quarter of fiscal 2025.

Zacks Equity Research

PACB Stock Rises After the Shipment of Vega Systems to Berry Genomics

by Zacks Equity Research

PacBio delivers the first Vega systems to Berry Genomics to develop and optimize its targeted assays to support screening programs in China and other markets.

Zacks Equity Research

AngioDynamics Stock Up on Q2 Earnings Beat, Gross Margin Declines

by Zacks Equity Research

ANGO registers overall strong top-line results on a pro-forma basis in second-quarter fiscal 2025, driven by strength in the Med Tech business.

Zacks Equity Research

Tempus AI Stock Falls Despite Collaboration Announcement With Genialis

by Zacks Equity Research

TEM announces a collaboration with Genialis to develop new RNA-based algorithms across cancer types.

Zacks Equity Research

Tandem Diabetes Forges New R&D Agreement With UVA: Stock to Gain?

by Zacks Equity Research

TNDM enters a multi-year research collaboration with the UVA Center for Diabetes Technology for the development of AID systems.

Zacks Equity Research

Here's Why You Should Retain OPKO Health Stock in Your Portfolio

by Zacks Equity Research

OPK's growth is fueled by Rayaldee's success and accelerated clinical trials. However, stiff competition and overdependence on its lead product are concerns.

Urmimala Biswas headshot

Abbott Stock Trades at a Discounted P/B Value: To Buy or Not to Buy?

by Urmimala Biswas

ABT gains a key position in point-of-care testing, focusing on Infectious Disease, Cardiometabolic & Informatics, Toxicology and Consumer Diagnostics.

Zacks Equity Research

BDSX Stock Rises After Publication of Study Data for Nodify CDT Test

by Zacks Equity Research

Biodesix announces positive study data for its Nodify CDT blood-based lung nodule test published in CHEST Pulmonary Journal.

Zacks Equity Research

Here's Why You Should Retain BDX Stock in Your Portfolio for Now

by Zacks Equity Research

BD's robust product portfolio and a few strategic deals raise optimism about the stock. However, stiff competition and macroeconomic volatility are concerns.

Zacks Equity Research

Abbott (ABT) Stock Falls Amid Market Uptick: What Investors Need to Know

by Zacks Equity Research

In the latest trading session, Abbott (ABT) closed at $113.04, marking a -0.69% move from the previous day.

Zacks Equity Research

TMCI Stock May Gain From the Limited Release of the Percuplasty System

by Zacks Equity Research

Treace Medical announces the limited market release of the Percuplasty Percutaneous 3D Bunion Correction System, targeting the in-demand bunion surgery market.

Zacks Equity Research

Omnicell Gains 26.2% in a Year: What's Driving the Stock?

by Zacks Equity Research

OMCL's shares rise on the back of its XT Amplify program gaining market traction with its initial offerings. However, the unfavorable macroeconomic scenario is concerning.

Zacks Equity Research

EssilorLuxottica to Acquire Pulse Audition: Will the Stock Rise?

by Zacks Equity Research

ESLOY is set to acquire Pulse Audition, an AI-driven tech startup, to strengthen its position in the hearing solution space.

Zacks Equity Research

Veracyte Gains 44% in a Year: What's Driving the Stock?

by Zacks Equity Research

VCYT is gaining shares due to the strength of its Afirma and Decipher tests.

Zacks Equity Research

HAE vs. ABT: Which Stock Is the Better Value Option?

by Zacks Equity Research

HAE vs. ABT: Which Stock Is the Better Value Option?

Zacks Equity Research

Are Medical Stocks Lagging Abbott Laboratories (ABT) This Year?

by Zacks Equity Research

Here is how Abbott (ABT) and Acurx Pharmaceuticals, Inc. (ACXP) have performed compared to their sector so far this year.

Zacks Equity Research

Cencora Stock May Gain Following the Strategic Acquisition of RCA

by Zacks Equity Research

COR completes the acquisition of Retina Consultants of America, marking a significant step in expanding its specialty healthcare and MSO solutions.